Anti-Aβ antibody target engagement

a response to Siemers et al

Andrew D Watt, Gabriela A N Crespi, Russell A Down, David B Ascher, Adam Gunn, Keyla A Perez, Catriona A McLean, Victor L Villemagne, Michael W Parker, Kevin J Barnham, Luke A Miles

Research output: Contribution to journalComment/debate

1 Citation (Scopus)


We have read with interest the commentary by Siemers et al. [28] regarding our paper describing the ability of the three anti-Aβ antibodies, bapineuzumab, crenezumab and solanezumab to engage Aβ in both a synthetic and a biological setting. We appreciate the opportunity to clarify any misunderstandings and here provide a brief response to their concerns.
Original languageEnglish
Pages (from-to)611-4
Number of pages4
JournalActa Neuropathologica
Issue number4
Publication statusPublished - 2014
Externally publishedYes


Cite this

Watt, A. D., Crespi, G. A. N., Down, R. A., Ascher, D. B., Gunn, A., Perez, K. A., ... Miles, L. A. (2014). Anti-Aβ antibody target engagement: a response to Siemers et al. Acta Neuropathologica, 128(4), 611-4.